Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-12-01 4:07 pm Purchase | 2022-11-23 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Integrated Core Strategies (US) LLC | 131,631 5.300% | 131,631 (New Position) | Filing History |
| 2022-06-09 3:20 pm Sale | 2022-05-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | BlackRock Inc. BLK | 117,707 4.800% | -2,233 (-1.86%) | Filing History |
| 2022-02-14 4:25 pm Sale | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Point72 Asset Management, L.P. | 2,244 0.100% | -114,948 (-98.09%) | Filing History |
| 2022-02-14 08:01 am Purchase | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | Nantahala Capital Management, LLC | 112,542 5.700% | 15,982 (+16.55%) | Filing History |
| 2022-02-14 06:40 am Purchase | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | BCLS II Equity Opportunities LP | 113,908 5.800% | 5,908 (+5.47%) | Filing History |
| 2022-02-11 4:12 pm Sale | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | ORBIMED ADVISORS LLC | 158,245 7.900% | -42,376 (-21.12%) | Filing History |
| 2022-02-10 5:03 pm Purchase | 2022-02-09 | 13D | Aeglea BioTherapeutics, Inc. AGLE | Baker Bros. Advisors LP | 201,779 9.900% | 5,732 (+2.92%) | Filing History |
| 2022-02-10 4:13 pm Purchase | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | ELI LILLY & Co LLY | 61,061 3.100% | 61,061 (New Position) | Filing History |
| 2022-02-10 11:14 am Purchase | 2022-02-09 | 13G | Spyre Therapeutics, Inc. SYRE | PICTET ASSET MANAGEMENT SA | 98,725 5.000% | 98,725 (New Position) | Filing History |
| 2022-02-10 09:01 am Sale | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | ADAGE CAPITAL PARTNERS GP L.L.C. | 40,000 2.030% | -79,680 (-66.58%) | Filing History |
| 2022-02-03 4:41 pm Sale | 2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE | BlackRock Inc. BLK | 119,939 6.100% | -9,660 (-7.45%) | Filing History |
| 2021-12-16 4:32 pm Purchase | 2021-12-06 | 13G | Aeglea BioTherapeutics, Inc. AGLE | SUVRETTA CAPITAL MANAGEMENT, LLC | 102,840 5.200% | 102,840 (New Position) | Filing History |
| 2021-03-19 4:07 pm Purchase | 2021-03-16 | 13D | Aeglea BioTherapeutics, Inc. AGLE | Baker Bros. Advisors LP | 196,048 9.900% | 346 (+0.18%) | Filing History |